Brought to you by 
FLX Bio's Series C round brings in $60mm
02 Jan 2018
Executive Summary
FLX Bio Inc. (immuno-oncology) raised $60mm in its Series C round. New investor GV took part, along with returning backers The Column Group, Kleiner Perkins Caufield & Byers, Topspin Partners, and Celgene. Proceeds will support the company's pipeline of regulatory T-cell and tumor myeloid cell modulators, including lead candidate FLX475, an oral CCR4 inhibitor that just entered Phase I for multiple tumor types.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
FLX Bio's Series C round brings in $60mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice